Evidence map›Paper›PMID 38967656›Full record

ArticleArchives of dermatological research2024

Tirbanibulin decreases cell proliferation and downregulates protein expression of oncogenic pathways in human papillomavirus containing HeLa cells.

Stephen Moore, Veda Kulkarni, Angela Moore, Jennifer R Landes, Rebecca Simonette, Qin He, Peter L Rady, Stephen K Tyring

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of dermatological research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Stephen MooreDepartment of Dermatology, The University of Texas McGovern Medical School, Houston, TX, USA.
Veda KulkarniDepartment of Dermatology, The University of Texas McGovern Medical School, Houston, TX, USA.
Angela MooreDepartment of Dermatology, Baylor University Medical Center Part of Baylor Scott and White, Dallas, TX, USA.
Jennifer R LandesDepartment of Dermatology, The University of Texas McGovern Medical School, Houston, TX, USA.
Rebecca SimonetteDepartment of Dermatology, The University of Texas McGovern Medical School, Houston, TX, USA.
Qin HeDepartment of Dermatology, The University of Texas McGovern Medical School, Houston, TX, USA.
Peter L RadyDepartment of Dermatology, The University of Texas McGovern Medical School, Houston, TX, USA.
Stephen K TyringDepartment of Dermatology, The University of Texas McGovern Medical School, Houston, TX, USA. styring@ccstexas.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tirbanibulin 1% ointment is a synthetic antiproliferative agent approved in 2021 by the European Union for treating actinic keratoses (AK). Topical tirbanibulin has clinically resolved HPV-57 ( +) squamous cell carcinoma (SCC), HPV-16 ( +) vulvar high-grade squamous intraepithelial lesion, epidermodysplasia verruciformis, and condyloma. We examined how tirbanibulin might affect HPV oncoprotein expression and affect other cellular pathways involved in cell proliferation and transformation. We treated the HeLa cell line, containing integrated HPV-18, with increasing doses of tirbanibulin to determine the effects on cell proliferation. Immunoblotting was performed with antibodies against the Src canonical pathway, HPV 18 E6 and E7 transcription regulation, apoptosis, and invasion and metastasis pathways. Cell proliferation assays with tirbanibulin determined the half-maximal inhibitory concentration (IC

Indexed as

Cell ProliferationDown-RegulationHuman papillomavirus 18Oncogene Proteins, ViralApoptosisDNA-Binding ProteinsFemaleHeLa CellsHuman Papillomavirus VirusesHumansPapillomavirus E7 ProteinsPapillomavirus InfectionsRepressor ProteinsSignal Transductionsrc-Family KinasesUterine Cervical NeoplasmsDNA-Binding ProteinsE6 protein, Human papillomavirus type 18E7 protein, Human papillomavirus type 18Oncogene Proteins, ViralPapillomavirus E7 ProteinsRepressor Proteinssrc-Family KinasesHuman papillomavirusNovel treatmentSkin diseaseTirbanibulinTopical treatment

Identifiers

PMID38967656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.